MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

Rhea-AI Summary

MaxCyte, Inc. (NASDAQ: MXCT) will release its fourth quarter and full year 2021 financial results on March 22, 2022, after U.S. market close. A conference call is scheduled for 4:30 p.m. Eastern Time to discuss the results. The company, recognized for its proprietary Flow Electroporation® platform, is focused on advancing cell-based research and the cell therapy market with its ExPERT™ platform. This technology supports various stages of cell therapeutic development and commercialization.

Positive

• The proprietary Flow Electroporation® platform enables complex engineering of diverse cells.
• The ExPERT™ platform supports the high-growth cell therapy sector from discovery to commercialization.

Negative

• None.

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22^nd, 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

Conference Call Details

Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers, (918) 922-6914 for international callers, for 0203 1070 289 U.K domestic callers, or for 0800 0288 438 U.K. international callers followed by Conference ID: 2675034. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.

About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 ir@maxcyte.com
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 maxcyte@consilium-comms.com

FAQ

When will MaxCyte release its financial results for Q4 and full year 2021?

MaxCyte will release its financial results on March 22, 2022.

What time is the MaxCyte financial results conference call?

The conference call will take place at 4:30 p.m. Eastern Time.

What technologies does MaxCyte focus on?

MaxCyte focuses on its Flow Electroporation® and ExPERT™ platforms for cell-based research and therapies.

What is the purpose of MaxCyte's ExPERT™ platform?

The ExPERT™ platform is designed to support the development and commercialization of cell therapies.

How can I access the live call for MaxCyte's financial results?

You can access the live call by dialing the provided numbers and using Conference ID: 2675034.